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Abstract
Background: Headache is a common complication of traumatic brain injury. The International Headache Society
defines post-traumatic headache as a secondary headache attributed to trauma or injury to the head that develops
within seven days following trauma. Acute post-traumatic headache resolves after 3 months, but persistent post-
traumatic headache usually lasts much longer and accounts for 4% of all secondary headache disorders.
Main body: The clinical features of post-traumatic headache after traumatic brain injury resemble various types of
primary headaches and the most frequent are migraine-like or tension-type-like phenotypes. The neuroimaging
studies that have compared persistent post-traumatic headache and migraine found different structural and
functional brain changes, although migraine and post-traumatic headache may be clinically similar. Therapy of
various clinical phenotypes of post-traumatic headache almost entirely mirrors the therapy of the corresponding
primary headache and are currently based on expert opinion rather than scientific evidence. Pharmacologic
therapies include both abortive and prophylactic agents with prophylaxis targeting comorbidities, especially
impaired sleep and post-traumatic disorder. There are also effective options for non-pharmacologic therapy of post-
traumatic headache, including cognitive-behavioral approaches, onabotulinum toxin injections, life-style
considerations, etc.
Conclusion: Notwithstanding some phenotypic similarities, persistent post-traumatic headache after traumatic brain
injury, is considered a separate phenomenon from migraine but available data is inconclusive. High-quality studies
are further required to investigate the pathophysiological mechanisms of this secondary headache, in order to
identify new targets for treatment and to prevent disability.
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Background
Traumatic brain injury (TBI) results from an external
mechanical force to the brain that usually leads to acute
or persistent headache, which is one of the most disabling
sequelae following trauma. According to the International
Classification of Headache Disorders (ICHD-III), post-
traumatic headache (PTH) is a secondary headache attrib-
uted to trauma or injury to the head that develops within
7 days: (i) following trauma, (ii) after regaining conscious-
ness and/or (iii) after recovering the ability to sense and
report pain [1]. Acute PTH is defined when the headache
resolves within 3 months after TBI, whereas persistent
PTH is characterized by headache lasting longer than 3
months.
Persistent PTH is frequent after mild TBI [2], account-
ing for 4% of all secondary headache disorders [3]. It is
estimated that 14 to 58% of patients with TBI will de-
velop a headache at 1 year after the trauma [4, 5] as
shown in Table 1. The one-year prevalence of persistent
PTH has been estimated 0.21% in Norway [6], whereas
the lifetime prevalence of PTH in Denmark is 4.7% in
men and 2.4% in women [7]. In a large cohort during
the first year after TBI, the incidence of new-onset
headache was 44% and the cumulative incidence of
headache at 12 months was 71%, with a 20% incidence
of persistent PTH [8].
Potential risk factors for developing persistent PTH in-
clude female gender, older age, presence of headache at
the emergency room and pre-existing headaches [9–11].
Migraine patients who developed PTH have a 2-fold in-
crease in the frequency and/or intensity of the headache
after the injury [8, 12], whereas PTH patients with pre-
existing tension-type headache also experience a slight
increase in attack frequency [5, 13]. Moreover, patients
with a family history of primary headache disorders have
an increase probability to develop PTH [14, 15]. In
addition, various surgical procedures in the craniofacial
region, such as a craniotomy followed by meningeal irri-
tation, have been attributed to cause different PTH phe-
notypes [16], however, the available data are very limited
and the underlying pathogenesis remains to be
stablished.
In contrast, the severity of headache, recovery time,
race, marital status, level of education, alcohol use at the
time of injury, the etiology of TBI and Glasgow Coma
Scale scores are not risk factors for the development of
Table 1 Comparison of the characteristics between persistent PTH and primary headaches
Persistent PTH Migraine Tension-type
headache
Cluster headache
Prevalence 18–58% after TBI 6–33% 62% 0.1%
Risk factors -Prior history of headache
-Female gender
- Older age
- Family history of headache
-Young age
-Female gender
-Anxiety
-Depression
-Young age
-Male gender
Duration of
episodes
Variable 180 min-3 days 30min-7 days 15–180min
Headache
symptoms
-Migraine-like
-Tension-type headache like
-Cluster like
-Severe intensity
-Unilateral location
-Pulsatile quality
-Aggravated by activity
-Mild/moderate
intensity
-Bilateral location
-Pressing quality
-Not aggravated
by activity
-Severe intensity
-Unilateral, orbital or
periorbital
Associated
symptoms
-Sleep disorders
-Affective and behavioral disorders
-Cognitive deficits
-Nausea or vomiting
-Photophobia and
phonophobia
-Photophobia,
phonophobia or
nausea
-Conjunctival injection, nasal
congestion, eyelid edema,
miosis, ptosis.
-Sense of restlessness or
agitation
Imaging (MRI) -Less cortical thickness in bilateral frontal
regions and right hemisphere parietal
regions of the brain
-Gray matter changes in the prefrontal
cortex.
-White matter
hyperintensities
-Normal -Normal
Neurophysiological
studies (EEG)
Early abnormalities (focal slowing, absence
of activity, amplitude asymmetries)
-H response to flicker
stimulation
-Abnormal resting-state EEG
rhythmic activity
Normal Normal
Treatment -Behavioral
-Drugs depending on phenotype
-Acute: NAIDs / triptans
-Preventive: β-blockers, anti-
epileptics, antihypertensive,
CGRP Abs
-Acute: NAIDs
-Preventive:
antidepressants
-Acute: triptans/O2
-Preventive: corticosteroids,
verapamil
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persistent PTH [9, 10, 17]. Although phenotypic similar-
ities between migraine and PTH have been demon-
strated in previous studies, i.e. throbbing headache, pain
on one side of the head, headache exacerbated by phys-
ical activities, moderate to severe pain, headache accom-
panied by nausea or vomiting, and photophobia and/or
phonophobia [18–22], the exact relationship between
persistent PTH and migraine remain largely unknown
and the shared pathophysiological mechanisms are con-
flicting [23]. In a neuroimaging study, Chong et al. found
that there were significant differences in fiber tract pro-
files between patients with migraine and persistent PTH
in the bilateral anterior thalamic radiations, cingulum,
longitudinal fasciculi, and uncinate fasciculi [24]. More-
over, it has been shown that regional brain volumes and
cortical thickness in patients with persistent PTH with
migrainous features and migraineurs revealed differences
in measurements of brain volume and/or thickness [25].
Thus, the aim of this review is to discuss if there is a
migrainous loop for persistent PTH and to provide a
better understanding of the underlying mechanisms of
migraine and headache attributed to TBI according to
current evidence.
Clinical presentation
Even though there are no major clinical features for per-
sistent PTH, its clinical presentation is usually character-
ized by heterogeneous symptoms such as nausea,
vomiting, headache after physical activity and stress,
headache exacerbated by light and sound, and impaired
cognitive and psychosocial functions [18]. These symp-
toms resemble those of various types of primary head-
aches, and the most frequent PTH phenotypes are
migraine-like or tension-type-like headache [4, 14].
Some studies report that tension-type-like headaches are
the most frequent [26, 27], while others show a higher
prevalence of migraine- like headache in patients with
PTH [5, 22]. In one study, for instance, tension-type-like
headache was reported in 97% of patients with de novo
headache after mild TBI and persistent PTH [27]. In an-
other study, a migraine-like headache or a probable
migraine-like headache was described in 49% of patients
with persistent PTH after mild TBI [5]. Even two other
studies [8, 13], showed migraine-like or probable
migraine-like headache in 53% of patients with headache
after moderate to severe TBI. Patients with migraine-like
PTH are more likely to have headache several days a
week or daily [13]; these patients have a higher probabil-
ity to have migraine 1 year after injury [5]. As mentioned
above, several studies have reported that individuals with
persistent PTH develop migrainous features, including
the throbbing headache, unilateral location, pain exacer-
bation by physical activities, moderate to severe pain,
headache accompanied by nausea or vomiting, and
photophobia and/or phonophobia [18–22]. However, in
some cases headache may be the only clinical manifest-
ation of PTH or it might be associated with cognitive
and psychological symptoms [28]. According to the data
reported in literature [27, 29], patients with persistent
PTH may also have post-traumatic stress disorder or
symptoms of anxiety and depression [11, 30]. It seems
that anxiety and depression are more common among
patients with persistent PTH than among migraineurs or
healthy controls [25]. In addition, patients with PTH
might suffer from autonomic dysfunction symptoms; the
most common autonomic symptoms are orthostatic in-
tolerance and bladder incontinence [31].
Less common PTH phenotypes are those similar to
trigeminal autonomic cephalalgias: hemicrania continua-
like [32, 33], chronic paroxysmal hemicrania-like [32,
34], cluster-like headache [32, 35] or short-lasting unilat-
eral neuralgiform headache attacks with conjunctival in-
jection and tearing (SUNCT). Patients with PTH might
simultaneously fulfill criteria for other secondary head-
aches - e.g. cervicogenic headache [36] or medication
overuse headache (MOH) [26, 27].
However, existing descriptive data concerning PTH
should be interpreted with caution due to substantial
methodological differences among studies [14, 26, 27].
Firstly, different inclusion criteria for (persistent) PTH
have been established in some studies, potentially weak-
ening evidence of causation - for example longer interval
between trauma and headache development [26, 27].
Typically, in prospective studies subjects were enrolled
within 1 week after head injury, while not in those retro-
spectives, possibly due to difficulties to obtain reliable
information from the patients’ medical records.
Another potential pitfall represents the inclusion of
patients with pre-existing headaches, as these individuals
are unlikely to represent the PTH prevalence rates of the
general population. If pre-existing headache patients are
included, the different clinical headache type onset ra-
ther than simple worsening of the same type of headache
should be required [26]. Further reason for discrepancies
among studies might be the enrollment of patients with
moderate or severe TBI, as there is as inverse relation-
ship between the severity of TBI and PTH occurrence,
with higher PTH rates in patients with mild TBI [26].
Moreover, about one third of patients suffering from
PTH display multiple head pain phenotypes [27].
Interesting data concerning the co-occurrence of PTH
and MOH have been provided by the Danish Headache
Center, a tertiary headache center. In a study conducted
between January 2001 and June 2003 among 53 patients
with persistent PTH, analgesic overuse was identified in
42% [26]. In a following study realized between June
2008 and August 2011, among 90 patients with persist-
ent PTH, only 13% of patients have had a MOH history
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during the PTH [27]. As suggested by the authors, these
results are not directly comparable due to different sam-
ple selections, but it might reflect an increased patient
awareness of the risk of developing MOH [27].
In conclusion, there are different variables which
might play a role in the assesment of patients with per-
sistent PTH. However, currently, the close temporal re-
lation between trauma and headache onset is a very
important element to make an appropriate diagnosis of
PTH.
Neuroimaging studies
Despite the high prevalence of PTH, there is still no
clear understanding of the pathophysiology of this head-
ache. The overlap of symptoms between persistent PTH
and migraine forces to speculate about a common
pathogenesis of these diseases, therefore, it could be very
useful to conduct neuroimaging research in this area.
Modern imaging techniques such as advanced magnetic
resonance imaging (MRI), diffusion tensor imaging
(DTI) and cerebral blood flow (CBF) measurements are
useful to assess brain changes even in the absence of sig-
nificant structural damages in mild TBI, which allows us
to use them to study PTH.
Neuroimaging studies in persistent PTH have been
performed to establish the brain structural [37–41] and
functional changes [42–45] that could explain its patho-
physiology, these include structural changes of the brain
volume and density by voxel-based morphometry [25,
37] and brain thickness [38]. The white matter changes
were studied by DTI measuring decreased fractional an-
isotropy, mean diffusivity and radial diffusivity and es-
tablishing the fiber tract profiles [24, 39]. The gray
matter changes in persistent PTH were measured by
gray matter volume [40] and voxel-based morphometry
[37]. The functional changes in the brain associated with
persistent PTH were studied using default mode net-
work [42], resting state MRI with static and dynamic
functional connectivity [43], perfusion weighted imaging
[46], CBF [45] and proton spectroscopy [44]. Some stud-
ies compare persistent PTH with healthy controls [25,
37–45] and others with migraine patients [24, 25, 43,
45]. The studies that have compared persistent PTH
with migraine, found structural [25, 38] and functional
brain changes [43] between groups, which suggest that
migraine and persistent PTH have different pathophysio-
logic mechanisms.
For example, Niu et al. conducted an MRI resting-
state functional connectivity study in 54 patients with
mild TBI (without pre-existing headaches) who devel-
oped acute PTH at 1- and 12-weeks following concus-
sion [42]. Patients with PTH at 12-weeks documented a
weaker baseline connectivity between the periaqueductal
gray, a brain area involved in opioid antinociception, and
the right inferior parietal lobule, a region of the default
mode network involved in introception and self-
reference [42]. The study concluded that disrupted peri-
aqueductal gray – default mode network functional
connectivity may be used as an early imaging biomarker
to identify patients at risk of developing PTH [42].
Moreover, a study conducted by Obermann et al. in 32
patients with whiplash injury without pre-existing head-
aches, found that patients who developed persistent
PTH, compared to healthy controls and patients affected
by acute PTH, showed a decreased anterior cingulate
and dorsolateral prefrontal cortex (DLPFC) gray matter
density, areas of the default mode and salience network
[37]. At an additional 12 months follow-up such differ-
ences were not present anymore, but an increased gray
matter density in areas of the midbrain, thalami and
cerebellum following persistent PTH resolution [37]. Ar-
guably, the latter finding might represent adaptive
changes to chronic pain processing [37]. These two
studies demonstrated the importance of gray matter
structural and functional changes over time in persistent
PTH.
Various studies compared neuroimaging advanced
measures of brain structure between persistent PTH,
mild TBI without headache and healthy controls. Rela-
tive to healthy controls, PTH patients have been found
to display reduced cortical thickness in various bilateral
frontal and right parietal regions, with headache burden
being negatively correlated to bilateral superior frontal
cortex thickness [38]. Relative to mild TBI patients who
do not developed headache, PTH patients had decreased
gray matter volumes within two large clusters described
as the right anterior-parietal and the left temporal-
opercular [40], areas previously reported to be involved
in both migraine and chronic pain [25].
Being migraine the usually clinical phenotype of (per-
sistent) PTH, it is not surprising that different authors
have investigated differences/overlaps between these two
conditions in order to delineate whether there might be
a common pathophysiology. Schwedt et al. compared
measures of brain regional volumes, cortical thickness,
surface area and brain curvature amongst twenty-eight:
migraine patients, individuals with persistent PTH fol-
lowing a TBI without history of pre-existing headaches
and healthy controls [25]. The authors found significant
differences in brain structures between persistent PTH
and migraine patients – namely the left precuneus, left
caudal middle frontal lobe, left superior frontal lobe,
right lateral orbitofrontal lobe and right supramarginal
gyrus – but only the last three regions were found to be
different between persistent PTH and healthy controls
and none between migraine patients and healthy
controls. This finding suggests a certain degree of brain
structures involvement/pathophysiological specificity
Labastida-Ramírez et al. The Journal of Headache and Pain           (2020) 21:55 Page 4 of 15
unique to persistent PTH regardless of the clinical
phenotype [25].
A recent study by Dumkrieger et al. [43] investigated
static and dynamic functional connectivity differences
between 44 patients with persistent PTH attributed to
mild TBI and 33 patients with migraine. Individuals with
pre-existing headaches were excluded, with the excep-
tion of infrequent episodic tension-type headaches. Sig-
nificant differences in static functional connectivity
between migraine and persistent PTH were found in up
to 17 region pairs that included the primary and second-
ary somatosensory cortex, insula, hypothalamus, anterior
cingulate, precuneus, ventromedial prefrontal and
DLPFC. Significant differences in dynamic functional
connectivity between migraine and PTH were found in
10 region pairs that included the secondary somatosen-
sory cortex, hypothalamus, middle cingulate, temporal
pole, superior parietal and parieto-occipital cortex, cin-
gulate and the amygdala. The majority of the afore men-
tioned brain areas are known to be involved in pain and
visual-processing. After controlling for sex and age, there
were significant correlations between years lived with
headache with static functional connectivity of right pri-
mary somatosensory with left supramarginal gyrus and
between headache frequency with static functional con-
nectivity of the cingulate-insula-hypothalamus network
in PTH patients [43]. This study demonstrates that per-
sistent PTH patients have different static and dynamic
functional connectivity compared with migraine patients
for regions involved in pain processing.
Gilkey et al. were among the first to demonstrate the
presence of structural brain changes in patients with
persistent PTH (with unknown pre-existing headache
history) attributed to mild TBI. In their pilot study, they
compared the regional CBF (rCBF) of 35 patients with
persistent PTH with minor TBI to 92 migraineurs and
49 healthy controls using the xenon 133 Xe inhalation
rCBF technique [45]. Compared to migraine patients
and healthy controls, patients with persistent PTH had
significantly reduced rCBF and greater regional and
hemispheric CBF asymmetries [45]. The authors sug-
gested that changes in CBF and vasomotor instability
with localized vascular hypersensitivity plays a pivotal
role in the pathogenesis of persistent PTH and other
symptoms associated with mild TBI [45].
Alhilali et al. compared DTI studies of 58 patients with
acute or persistent PTH of a migraine phenotype with un-
known pre-existing headache history, with 17 patients
with mild TBI without headache [39]. It was found that
patients with headache had decreased fractional anisot-
ropy in the corpus callosum and fornix/septohippocampal
circuit [39]. In contrast to the above studies, this observa-
tion allows us to consider the possibility of a common
pathophysiological mechanism between persistent PTH
and migraine, since white matter changes in the corpus
callosum have also been identified in patients with mi-
graine [39].
On the other hand, Chong et al. [24] demonstrated
differences of white matter changes in patients with
PTH without history of pre-existing headache, compared
to migraine patients. In this DTI study the authors com-
pared 49 patients with persistent PTH attributed to mild
TBI to 41 patients with migraine and 41 healthy controls
[24]. Node-by-node diffusion parameters (mean diffusiv-
ity and radial diffusivity) were calculated per groups. A
significant difference of mean diffusivity or radial diffu-
sivity in the bilateral anterior thalamic radiations, cingu-
lum (angular bundles and cingulate gyri), inferior
longitudinal fasciculi, and uncinate fasciculi, the left cor-
ticospinal tract, and the right superior longitudinal
fasciculi-parietal portion was revealed between patients
with persistent PTH and migraine patients. Also, in pa-
tients with PTH a positive correlation was found be-
tween headache frequency and cingulate angular bundle
diffusion parameters, which were not observed in pa-
tients with migraine. The authors concluded that
disease-specific differences between groups might sug-
gest different pathophysiological mechanisms underlying
these conditions [24].
As follows from the above listed facts, there is more
evidence of brain structural differences in migraine pa-
tients and patients with persistent PTH, which allows us
to consider these types of headache as distinct noso-
logical entities. However, high-quality studies are further
required to investigate the structural brain changes spe-
cific to PTH.
Neurophysiological studies
Electroencephalography (EEG)
Electroencephalographic studies in PTH are sparse and
the few available often show marked early abnormalities,
these include focal slowing, absence of fast activity and
amplitude asymmetries [47–49]. Torres and Shapiro re-
ported abnormalities in 44% of patients of a group with
mild closed head injuries compared to a group with
whiplash injury alone [48]. A more recent study on pa-
tients with mild or minor closed head injuries, selected
on the basis of of lack of unconsciousness on admission
and normal neurological examinations, revealed 54%
with focal and diffuse slowing EEG abnormalities [49].
The EEG may be abnormal immediately after injury,
but it often normalizes within minutes to weeks. Persist-
ent findings that were once considered abnormal are
now considered normal variants, having the same inci-
dence as in the general population [50]. Quantitative
EEG may or may not be useful in head injury. In one
small study, quantitative EEG showed a statistically sig-
nificant increase in both slow and fast activities over the
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temporal region of the skull [51]. However, the authors
concluded that this test offers little benefit to the patient
with PTH, since there is a great variability within both
PTH and healthy controls [51]. Another study examined
the ability of power spectrum analysis to discriminate
between 608 head injury patients and 108-age matched
controls with more than 90% accuracy [52]. No correl-
ation was made between the symptoms of PTH or post-
traumatic syndrome and abnormal test results [52].
Therefore, the predictive value of this analysis is uncer-
tain at this time. In general, these studies indicate that
PTH patients, as a group, differ from non-headache con-
trols; but unlike the study of Ramadan et al. [53], they
cannot reliably differentiate an individual PTH patient
from an idiopathic headache patient.
Contrary to what has been observed in PTH patients,
several previous EEG studies emphasized abnormal elec-
trocortical activities in migraine patients. The most
frequently described electrocortical phenomena in
migraineurs were the so-called H response to flicker
stimulation – also known as enhanced photic driving
(PD) – and the abnormal resting-state EEG rhythmic ac-
tivity [54]. Enhanced PD of EEG during intermittent
photic stimulation using fast Fourier transform analysis
on steady-state visual evoked potentials (VEP), the so-
called H response, was more prevalent in migraine pa-
tients than in healthy controls. Researchers observed
that the fundamental components of the EEG spectra
were increased equally in both migraine with aura (MA)
and migraine without aura (MO) patients [55], predom-
inantly in the temporo-parietal regions, with reduced in-
terhemispheric coherence in fronto-temporo-parietal
areas [54, 55]. De Tommaso et al. observed that, al-
though in both MO and MA groups PD was significantly
enhanced with respect to controls, those patients experi-
encing aura showed more pronounced decreased phase
synchronization between beta rhythms and higher
Granger causality values – measuring the flow of con-
nections and information across different brain areas –
during light stimulation compared to MO patients [56].
During the interictal period of MA patients, the quanti-
tative analysis of spontaneous electroencephalographic
activity showed alpha rhythm and peak frequency asym-
metries over the posterior regions, increased power of
alpha rhythm, and widespread increase in delta and theta
total power in comparison with healthy controls [54].
Reduction of alpha rhythm or unilateral reduction of
alpha and theta activity was detected in MA patients
with a pure visual aura, mostly contralateral to the
neurological signs [57]. MA patients had greater alpha
peak power interhemispheric asymmetry, chiefly in the
posterior regions, and unrelated to the headache side,
than MO [54]. In conclusion, EEG studies confirm that
despite significant overlap in symptoms between PTH
and migraine, there are identifiable neurophysiological
differences in brain function, perhaps suggesting distinct
underlying pathophysiology between the two headache
types.
Evoked potentials
Short-latency somatosensory evoked potentials have not
been shown to have an important value in testing pa-
tients with head injury or post-traumatic headache [12].
Brain-stem auditory evoked potentials have been found
to be abnormal in 10% to 20% of patients with head in-
jury and post-concussion syndrome, more frequently in
those with prolonged unconsciousness [50]. They can ei-
ther improve or deteriorate from 2 days to 1 month after
injury [58]. Symptomatic dizziness does not correlate
with brainstem auditory evoked potential abnormalities
[58]. While the brainstem auditory evoked potential sep-
arates groups of PTH patients from groups of controls,
it is of no value in distinguishing an individual with
post-traumatic syndrome from one without it.
On the other hand, higher cortical response ampli-
tudes, an increased interhemispheric response asym-
metry, and a deficit of response amplitude decrement
were demonstrated by using different types of sensory
stimuli and techniques in most MA patients [54]. Be-
cause in most cases the aura is visual, the major part of
the published studies investigated VEPs to search for
cerebral signatures associated with MA. By analyzing the
evoked responses in a classical way of averaging a large
quantity of trials, mainly increased amplitudes of steady-
state (SS) or transient VEPs have been discovered in MA
patients during attack-free intervals [54]. In some re-
ports the grand-average of VEP N75-P100 and/or P100-
N145 amplitudes has been found greater in MA patients
than in controls and/or in MO patients [54, 59, 60]. In
addition, decreased amplitude of the prerolandic compo-
nent (N20) of somatosensory evoked potentials in both
MO and MA patients has been found in one study [61],
but amplitudes were within the normal range in other
[62]. Most of the researchers who recorded short-latency
brainstem auditory evoked potentials were not able to
find any interictal abnormalities in migraine, probably
because they pooled patients with different migraine
phenotypes (MO and MA or different MA subtypes) in
different proportions in a single group [63].
The role of P300, an event-related potential, in evalu-
ating PTH patients is also uncertain up to date. One
study demonstrated significant abnormalities of P300
amplitude and latency in 20 head injury patients com-
pared with 20 control subjects [64]. Werner and Vander-
zant found an abnormal response in only one of 18
patients [65]. Kobylarz et al. reported a correlation be-
tween an abnormal P300 and an abnormal MRI [66]. An
interesting study demonstrated that hearing accident-
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related words (i.e., “stressful”) produced a significantly
larger P300 than hearing neutral words in patients with
mild head injury but not in non-head injury controls.
The P300 amplitude difference correlated with the pa-
tient’s two-way state anxiety score [67].
Nevertheless, enough studies suggested that basic
P300 amplitude tended to be the greatest in a mixed
group of MO and MA patients compared with con-
trols and other types of headaches [54]. P300 ampli-
tude was significantly reduced during mind wandering
relative to on-task periods in migraineurs, contrasting
to what happened in healthy controls [54, 68]. The
authors argued that a more consistent propensity to-
wards engaging in response attenuation during mind
wandering states may provide migraineurs with an al-
ternative compensatory strategy for reducing stimulus
overload in cortex [68].
Electronystagmogram is abnormal in 40–50% of pa-
tients with head injury or “whiplash” in clinic-based
studies. Toglia examined 150 patients who complained
of vestibular symptoms following either head injury or
whiplash injury, searching for spontaneous, latent, and
positional nystagmus [69]. Bithermal caloric tests and
rotational tests were performed when possible. Abnor-
mal caloric tests (including both canal paresis and dir-
ectional preponderance) were found in 63% of head
injury patients. Abnormal rotatory tests were found in
9 of 16 whiplash patients (56%) and 20 of 24 head in-
jury patients (83%) [69]. Rowe and Carlson studied 19
patients with post-concussive dizziness following head
injury and found that 11 patients (58%) had abnormal-
ities consisting of latent or positional nystagmus or
calorie-induced nystagmus [70]. None of these patients,
who had abnormal brainstem auditory evoked poten-
tials (3 standard deviations), showed a normal electro-
nystagmogram. Conversely, most patients with
abnormal electronystagmograms had normal brainstem
auditory evoked potentials [70]. This suggests that the
electronystagmogram may be more sensitive than the
brainstem auditory evoked potential. Mallinson and
Longridge found electronystagmogram abnormalities in
patients with whiplash injury and mild head injury, but
not in whiplash injury alone, although symptoms of diz-
ziness were similar in both groups [71]. Computerized
dynamic posturography was studied in a referral popu-
lation of dizzy patients after whiplash injury, alone or
with mild head injury. Both groups had positive find-
ings, although the type of posturography abnormality
was different between groups [71]. To summarize,
evoked potentials can also be used to detect post-
traumatic neurophysiological changes in PTH patients,
but they are relatively subtle and may be challenging to
distinguish from those seen in other conditions such as
migraine.
Treatment
As previously discussed, persistent PTH can resemble
the clinical features of migraine, tension-type headache
or other primary headache disorders, but the signs and
symptoms are often mixed in nature and can be challen-
ging to manage. Also, the impact of external factors such
as psychosocial and legal circumstances surrounding the
injury must be taken into account, since post-traumatic
stress disorder is known to co-occur and affect the in-
tensity of persistent PTH [72, 73]. Currently, there is no
available data from randomized controlled trials evaluat-
ing the therapeutic efficacy of medical interventions spe-
cific to persistent PTH, therefore, the therapy mirrors
conventional treatment approaches for non-traumatic
primary headache disorders [74]. Many experts agree
that persistent PTH should be treated “according to the
class of headache its characteristics most closely resem-
ble” [3, 18, 75]. However, this approach lacks evidence
and often results in poor treatment responses [76]. It is
also important to use personalized medicine which re-
quires a clinical approach integrated with the use of
pharmacological and physiotherapeutic strategies as well
as educational and behavioral interventions, often com-
bined among them, because the multidisciplinary ap-
proach to treatment is likely to be most efficacious in
the treatment of persistent PTH [77].
The selection of an appropriate pharmacologic therapy
for treating persistent PTH includes consideration of
abortive medications that stop the acute pain attack, and
often a prophylactic medication that focuses on decreas-
ing the attack frequency. The choice of particular agents
depends on their efficacy for the primary headache it is
resembling, side-effect profiles, and patient comorbidi-
ties [78]. Since we believe that persistent PTH is not a
migrainous loop, and it has been shown that it often
mimics a migraine-like or tension-type headache-like
phenotype [79], we discuss persistent PTH treatments
based on the different headache presentations.
Pharmacological treatment of persistent PTH
Persistent PTH resembling tension-type headache (TTH)
Standard pharmacologic interventions for TTH include
over-the-counter preparations, non-steroidal anti-
inflammatory drugs and rarely opioids. Regardless of the
agent employed, successful headache treatment is most
likely if the medication is taken at the onset of a head-
ache rather than waiting for the headache pain to escal-
ate. Common over-the-counter medications trialed by
patients include acetaminophen (paracetamol), aspirin,
ibuprofen, and naproxen, all of which may come in com-
bination with caffeine. Opioid medications are rarely in-
dicated to treat a severe refractory headache; caution
must be used, however, as repeated use of opioids can
lead to addiction and, similar to other analgesics, MOH,
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therefore they should be avoided in the treatment of
PTH [80–82].
As discussed above, persistent PTH resembling
chronic tension-type headache is one of the most or the
most common headache type presentation in studies
performed in PTH [4, 26, 27, 83]. Patients with chronic
or very high-frequency TTH are in need of prophylactic
therapies [84, 85]. Treatment is primarily based on the
treatment of chronic tension-type headache. Retrospect-
ive studies in populations with persistent PTH showed
that prophylactic medication with amitriptyline is an ef-
fective treatment [26, 86]. Experts in the field also rec-
ommend the use of nortriptyline, the metabolite of
amitriptyline, which shows better tolerability due to
lower anticholinergic side effects [87].
Persistent PTH resembling migraine
In migraine, potential abortive agents include the same
medications as in tension-type headache, but also trip-
tans, and, less commonly, ergot derivatives or opioids
among others. Triptans are selective serotonin receptor
agonists acting at the 5-HT1B/1D/(1F) receptors present in
the trigeminovascular system. These agents have shown
a well-defined efficacy in multiple clinical trials and hold
a level A recommendation for use in the abortive treat-
ment of migraine [79]. Other treatment options for
migrainous headaches includes antiemetic agents.
Agents such as metoclopramide, promethazine, and pro-
chlorperazine may also be tested in patients that are re-
fractory to specific migraine treatments. A potential
advantage to the use of these medications is the lack of
risk of rebound headache [88].
When the decision has been made to initiate prophy-
lactic therapy for PTH, the selection of a specific agent
usually depends on the comorbidities (i.e., amitriptyline
should be considered if the patients have concomitant
insomnia or β-blockers if concomitant hypertension)
and contraindications (β -blockers/Calcium-channel
blockers should be avoided if the patient has arterial
hypotension, tricyclic antidepressants in the case of ex-
cessive fatigue, QT prolongation, increased ocular tone,
etc.) [89]. There are many classes of drugs, which have
been employed for the prophylaxis of migrainous
headaches.
Prophylactic choices include β-blockers (which have
particular utility in patients with anxiety as they may de-
crease the physical autonomic symptoms of anxiety); tri-
cyclic antidepressants, which are particularly effective in
patients with depression or sleep disturbances; calcium
channel blockers, valproic acid, topiramate, gabapentin,
and onabotulinum toxin A. However, in a study where
PTHs were primarily resembling migraine, tricyclic anti-
depressants in low doses (25–50 mg of amitriptyline
daily) were found to be not effective and the authors
conclude that amitriptyline, when used, should be ti-
trated up to higher doses to be effective [21].
There has been some exploration of naturopathic
agents such as feverfew and butterbur, as well as supple-
ments such as magnesium, riboflavin (vitamin B2) and
coenzyme Q10. Magnesium may be effective as a
prophylactic treatment with 400mg daily of chelated
magnesium, magnesium oxide or slow-release magne-
sium in patients with symptoms suggestive of hypomag-
nesemia, such as migraine headaches, premenstrual
syndrome, cold extremities and leg or foot muscle
cramps [90]. There are positive but small controlled tri-
als for riboflavin [91] and coenzyme Q10 [92] and stron-
ger evidence for butterbur [93]. Unfortunately, concerns
have been raised regarding the preparation process for
commercially available butterbur with potential for hep-
atotoxicity [94, 95].
Persistent PTH resembling trigeminal autonomic
Cephalalgias (TACs)
There are few case reports of cluster headache occurring
after trauma and most of these do not fulfill the seven-
day criteria for PTH, but a correlation between head in-
juries and cluster headaches has been reported, although
it is unclear if head trauma is causative for the develop-
ment of cluster headache or if cluster headache is associ-
ated with a higher risk of head trauma [96]. In the cases
with cluster headache following the incident within 7
days, headache always appeared on the side of the
trauma and the treatment of choice are the same agents
as in primary cluster headache, with sumatriptan, oxygen
or intravenous dihydroergotamine [97] as abortive medi-
cation and verapamil as preventive agent [98].
There is a small number of case reports of successful
treatment of PTH with indomethacin appearing as hemi-
crania continua and paroxysmal hemicrania [33, 34, 99].
There are two cases reported with persistent PTH
appearing as Short-Lasting Unilateral Headache With
Cranial Autonomic Symptoms (SUNA) showing success-
ful treatment with gabapentin or carbamazepine [100].
Medication overuse headache (MOH)
There is a significant risk of MOH in the PTH popula-
tion [101], with the use of over-the-counter and other
analgesics leading to an overall increase in headache fre-
quency. MOH in PTH often resembles the underlying
headache type, therefore also appearing resembling TTH
or migraine [102, 103]. Analgesic overuse was recorded
in 19 to 42% of the study populations and a significant
part of these patients improved after discontinuation of
the overuse [26, 83]. Therefore, MOH should always be
considered when assessing patients with persistent PTH
and analgesic medication withdrawal is the treatment of
choice.
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Anti-CGRP monoclonal antibodies
Calcitonin Gene-Related Peptide (CGRP) is a potent en-
dogenous vasodilator and neurotransmitter, which is in-
volved in the pathophysiology of migraine and has been
a target for drug development in recent years [104–106].
In experiments, it has been shown that the activation of
the trigeminal ganglion leads to the release of CGRP
[107]. Anti-CGRP monoclonal antibodies such as erenu-
mab, eptinezumab, fremanezumab and galcanezumab
have shown to be effective for preventive treatment of
episodic and chronic migraine and are currently ap-
proved (erenumab, fremanezumab, galcanezumab) or are
expected to seek approval (eptinezumab) from the Euro-
pean Commission for preventive treatment of episodic
and chronic migraine [108–111]. As described above,
the clinical appearance of PTH often resembles mi-
graine, therefore it is commonly assumed that there may
be a similar use case in the treatment of PTH with
migraine-like features. Recent experiments in rodent
models have shown CGRP involvement and efficacy of
anti-CGRP monoclonal antibodies in PTH [112, 113].
Currently, there is only one observational clinical study
completed, evaluating the treatment of PTH appearing
as migraine phenotype with erenumab in 7 patients,
which showed exceptional efficacy of 140 mg erenumab
measured in reduction of headache days and Head Im-
pact Test-6 [114]. Impressively, in most of these cases
there was only one application of erenumab required for
stable remission of the symptoms in the follow-up over
6 months, only in one patient the erenumab dose was
administered twice. However, the small quantity of pa-
tients and the fact that three of them had pre-existing
migraine, limits the generalization of these results.
Hence, this work should be interpreted cautiously, since
it is unlikely to reliably reflect data from the ongoing
clinical trials with erenumab for PTH prevention.
On the publishing date of this review, there are two stud-
ies currently recruiting for treatment of PTH with erenu-
mab (NCT03974360) and fremanezumab (NCT03347188),
although only the study with fremanezumab is placebo-
controlled [115, 116]. In conclusion, at the moment there is
a high need for the clinical trial results, but there is growing
evidence for the efficacy of anti-CGRP monoclonal anti-
bodies in persistent PTH and they are likely to be a promis-
ing future treatment of persistent PTH with migraine
phenotype.
Other treatment approaches
There are different techniques of injections with
onabotulinum toxin A, local anesthetics and steroids
currently used in the treatment of primary headache
disorders and therefore also available in persistent
PTH.
Onabotulinum toxin injections
At present, Botulinum Toxin (BTX) injection is the only
FDA-approved medication for chronic migraine. There are
a few case reports showing the efficacy of BTX in the treat-
ment of persistent PTH. The most extensive study looked
at the charts of 64 male servicemen age 20 to 50 who pre-
sented to the Concussion Care Clinic of Womack Army
Medical Center in Fort Bragg North Carolina between 2008
and 2012 [117]. Of those patients, 36 (56.3%) had more
than one type of headache, ten (15.6%) had more than two
headaches, and 48 subjects (75%) had continuous headache.
Forty-one patients (64%) reported that they were better
after treatment, 18 (28%) were unchanged, two (3%) were
worse, and three patients were lost to follow-up. Common
side effects included headache and neck pain. In this au-
thor’s experience, these patients showed a significant im-
provement in their headaches and associated concussion
symptoms after treatment with BTX.
Nerve blocks
Peripheral nerve blocks are one of the most widely used
interventional procedures to treat persistent PTH [118].
Common sites include the greater occipital nerve, lesser
occipital nerve, auriculotemporal nerve, supraorbital
nerve, supratrochlear nerve, and sphenopalatine ganglion
(SPG). Interventions include blocking a single nerve uni-
laterally, bilaterally or multiple nerves. The rationale be-
ing that local anesthetic to these nerves results in a
decrease afferent feedback to the trigeminal nucleus cau-
dalis, decreasing nociceptive transmission [119]. Typical
anesthetics include bupivacaine (0.25 to 0.75%) or lido-
caine (2%), with volumes ranging from 0.5 to 2 cc per
site. Local anesthetics inhibit nerve fiber conduction by
reversibly inhibiting sodium channels and can act on un-
myelinated C-fibers and thinly myelinated Aδ fibers that
mediate pain. Local anesthetics can be given alone, com-
bined with each other and/or with a steroid. In a single-
blind randomized controlled trial, Ashkenazi et al. com-
pared the effect of lidocaine with triamcinolone vs. lido-
caine alone in patients with transformed migraine [120].
No statistically significant differences were seen in any
of the outcome measures between the two groups.
Trigger point (TP) injections
Common sites include the occipitalis, frontalis, masseter,
temporalis, trapezius, levator scapulae, semispinalis capi-
tis, splenius and sternocleidomastoid. The pathophysio-
logical mechanisms underlying TPs are poorly
understood. Therefore, in theory, amelioration of TP in
the head and neck should result in a decrease in head-
ache. As is the case with peripheral nerve blocks, TP in-
jections can be performed with lidocaine and/or
bupivacaine, but steroids are also often used. After loca-
tion of the trigger point via palpation, multiple sites are
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often injected, 1 to 2 cc per site using a 0.5- to 1-in. nee-
dle. Unfortunately, there are no studies looking at the
treatment of trigger points in PTH.
Non-drug treatments
Apart from drug-based therapies, several different non-
drug treatments are currently used in the therapeutic ap-
proach in primary headaches, especially in migraine and
TTH. Persistent PTH is often over-medicated with both
prescription and over the counter pharmacotherapies
[102, 121], therefore, a systematic management program
that is headed toward reducing polypharmacy in persist-
ent PTH patients can improve patient safety and reduce
hospitalizations from the burden of headaches [122].
Physical medicine
There are very few studies that specifically look at phys-
ical therapy, massage therapy, spinal manipulation, and
mobilization as a treatment for persistent PTH. In a
case-control study [123], patients underwent physiother-
apy by unblinded physical therapists with the primary
endpoint being the change in headache intensity. The
patients were randomly assigned to receive either man-
ual therapy for the cervical region (usual care group) or
additional manual therapy techniques to the temporo-
mandibular region. Patients in the treatment group ex-
perienced statistically significant decreases in headache
intensity at 3 and 6months when compared to the usual
care group. Two other modalities that have received
considerable study are spinal manipulation and
mobilization. When addressing the cervical spine,
mobilization techniques are safer than manipulation
techniques, which can be associated with adverse effects
(i.e., disc herniation and arterial dissection).
Youssef et al. compared the efficacy of spinal
mobilization with massage therapy in patients with
cervicogenic headache [124]. Thirty-six subjects were
randomized with eighteen receiving passive spinal
mobilization for 30–40 min, and the other eighteen re-
ceiving massage therapy, myofascial release, traction,
and stretching exercises. Both groups were treated for
12 sessions (2× per week for 6 weeks). Outcome mea-
sures included decrease in headache intensity, frequency,
and duration, as well as improvement in cervical pain
and range of motion. Both groups experienced signifi-
cant improvements in all measured variables with the
mobilization group experiencing statistically significant
reductions in all variables when compared to the mas-
sage group [124]. Moreover, a case report by Channell
et al. showed that a multidisciplinary approach, includ-
ing medications and osteopathic manipulation, was ef-
fective in treating a 38-year-old female with chronic
PTH [125].
Repetitive Transcranial magnetic stimulation (TMS)
TMS is a non-invasive neurostimulation procedure in
which cerebral electrical activity is influenced by a
pulsed magnetic field. An electric current briefly passing
through a copper-wire coil generates the magnetic field.
When this coil is placed on the head, its magnetic field
induces small currents in an area of the brain directly
under the coil. In repetitive TMS (rTMS), repeated sin-
gle magnetic pulses of similar intensity are delivered
over a targeted brain region.
One recent study by Leung et al. showed the benefits
of rTMS treatment to the DLPFC in participants with
mild TBI related headache [126]. They reported an aver-
age daily persistent headache intensity reduction at both
one and 4 weeks following rTMS when compared to
baseline. In addition, they found a significant reduction
in the depression rating score at 1 week.
Similarly, Stilling et al. performed a double-blind, ran-
domized, sham-controlled, pilot clinical trial on twenty par-
ticipants (18–65 years) with persistent PTH and persistent
post-concussion symptoms (PPCS) [127]. Ten sessions of
rTMS therapy (10Hz, 600 pulses) were delivered to the left
DLPFC. The primary outcome was a change in headache
frequency or severity at one-month post-rTMS. Two-week
long daily headache diaries and clinical questionnaires
assessing function, PPCS, cognition, quality of life, and
mood were completed at baseline, post-treatment, and at
one-, three-, and six-months post-rTMS. Secondary out-
comes revealed an overall time interaction for headache im-
pact, depression, post-concussion symptoms, and quality of
life. This pilot study demonstrates an overall time effect on
headache severity, functional impact, depression, PPCS, and
quality of life following rTMS treatment in participants
with persistent PTH, however, findings were below clinical
significance thresholds. Since there was a 100% response
rate, no dropouts, and minimal adverse effects, future larger
studies are warrant.
Surgical decompression
Four different decompression procedures are performed
based on the headache location, i.e., frontal, temporal,
occipital, and sinus regions. The theory behind these
procedures is that peripheral nerve compression in the
head and neck can serve as a migraine trigger. Two
studies have been published. The first study (placebo-
controlled) enrolled 76 patients based on their response
to BTX, with 49 receiving actual surgery and 26 receiv-
ing sham surgery [128]. The primary endpoint was a
50% reduction in migraine headache days. The baseline
headache frequency of the subjects in the intervention
group was 9.9 (±6.0) per month and 9.5 (±4.4) in the
control group. At 1-year post surgery, 28 subjects re-
ported complete resolution of their migraine headaches,
with 41 reporting significant improvement. Of the 26
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subjects who received sham surgery, one reported
complete resolution of their migraine headaches, and 15
reported significant improvement.
The second study [129], a 5-year outcome study in-
cluded 125 randomly assigned patients. The treatment
group had a single surgery or a combination of proce-
dures with follow-up at 1 and 5 years, while the placebo
group received saline injections. Sixty-nine patients were
eventually included in the final analysis with 9% having a
single-site procedure, 22% having surgery at two sites,
44% at three sites, and 26% at four sites. Twenty subjects
(29%) had complete resolution of their headaches, and
41 (59%) had significant improvement defined as a 50%
reduction of frequency, intensity, or duration.
Interestingly, a recent retrospective review of 28 con-
secutive cases of patients with post-concussion head-
aches mirrors the above studies [130]. In this case, all
patients had persistent PTH for at least 3 to 6 months
and they underwent occipital nerve surgery including
decompression or excision of the greater, lesser, or third
occipital nerves. Those with headaches centered in the
temple area underwent transection of the anterior
branch of the auriculotemporal nerve or zygomaticotem-
poral nerve, and those with frontal headaches underwent
decompression of the supraorbital, supratrochlear, and
infratrochlear nerves. Preoperative and postoperative
headache pain was evaluated with the visual analog scale
(VAS) in 24 patients with at least 6-month follow-up. Of
these patients, twenty-one (88%) had a successful outcome
of at least a 50% reduction in their VAS following periph-
eral nerve surgery, and 12 patients (50%) were pain-free at
the end of follow up, while eight patients required a sec-
ond procedure, and four underwent a third procedure,
which included readdressing the occipital region. The au-
thors suggest that patients with concussion may experi-
ence a traction stretch injury to their peripheral nerves,
which can then act as a potential pain generator.
There are numerous interventional procedures avail-
able for patients with acute, chronic, and refractory
PTH, unfortunately, no prospective controlled trials exist
and these are clearly needed. A multidisciplinary ap-
proach is preferred, therefore, in the acute phase, com-
bining physical therapy with peripheral nerve blocks,
trigger point injections and abortive medications is sug-
gested, while in some cases preventative medications will
more than likely yield the best outcome.
Intranasal block of the SPG
This intervention has been shown to be effective in the
treatment of chronic migraine. A double-blind placebo-
controlled study by Cady et al. looked at repetitive SPG
blocks with 0.5% bupivacaine in chronic migraine treat-
ment [131]. Thirty-eight patients received treatment
twice a week for 6 weeks. Patients receiving bupivacaine
reported on average 5.71 fewer headache days than pla-
cebo, a reduction in acute medication usage and im-
proved quality of life measures.
A recent case report in sport-related PTH found simi-
lar efficacy in a patient having failed oral preventive
measures [132]. After SPG block, this patient experi-
enced resolution of headache and ultimately returned to
school and sports without recurrence of symptoms dur-
ing 6months post-procedure.
Behavioral treatment
Martin et al. [133] developed a novel behavioral treatment
approach for chronic primary headaches, referred to as
“Learning to Cope with Triggers” (LCT). Triggers, most
commonly stress, hormonal factors, light flicker or glare,
noise, odors, certain foods, alcohol, weather changes, and
fatigue often precede headaches. Health professionals and
education materials typically advise avoidance of such trig-
gers as good “headache hygiene.” However, avoidance be-
havior can become excessive, where pain-related fear and
avoidance behavior contribute to disability in chronic
headache sufferers. In response, Martin et al. designed a
behavioral intervention that involves graded exposure to
triggers. The rationale depends on the nature of the par-
ticular trigger. Graded exposure could serve as experi-
ments to learn which alleged triggers do in fact reliably
precipitate headaches, promote habituation, and/or pro-
vide opportunity to practice applying new coping skills.
The intensity and frequency of exposures are progressively
increased at a pace that is insufficient to provoke head-
aches, in collaboration with the patient. Avoidance is rec-
ommended over exposure for unhealthy triggers, such as
dehydration, alcohol use, and inadequate sleep.
In a randomized controlled trial with patients who had
chronic daily headaches of various types, LCT resulted
in improved headache ratings and reduced medication
use in comparison to avoidance coaching and wait-list
control groups. The LCT approach may be especially
well-suited to persisting PTH following mild TBI [134].
It has been recently shown that patients with persisting
PTH after mild TBI identify a similar pattern of triggers
as those in primary headache disorders, but perceive
mental exertion as a particularly potent headache pre-
cipitant that they try to avoid. This “cogniphobia” is as-
sociated with headache frequency and intensity, and
possibly reduced neuropsychological performance after
mild TBI [135]. Cogniphobia could be easily added as a
treatment target in LCT. There is also emerging
evidence that an avoidant coping style is associated with
poor outcome after mild TBI. By introducing alternatives
to avoidant coping in the context of headache manage-
ment, LCT may teach adaptive coping skills that
generalize beyond headache management and improve
other symptoms after mild TBI.
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Sleep
Adequate sleep may play an important role in the evolu-
tion of headache disorders after TBI. Insomnia may be re-
ported in the post-TBI population associated with
headaches, evolving mood disturbance, or as one of the
acute-onset symptoms of the head injury itself. TBI pa-
tients have reduced REM sleep (with increased slow-wave
sleep) and produce lower levels of evening melatonin
[136]. Obstructive sleep apnea, restless leg syndrome, and
periodic limb movements of sleep are more common in
the TBI population as well [137]. Sleep disturbance may
contribute to the exacerbation of headache disorders and
daytime cognitive complaints. It has also been postulated
that insomnia reduces inhibitory pain control [138]. Con-
current use of benzodiazepines for indications such as
anxiety, muscle spasm, or insomnia may also aggravate
posttraumatic cognitive symptoms (even after discontinu-
ation) as well as depression and should, therefore, be
avoided when possible [139, 140].
Other lifestyle considerations
Self-medicating behaviors of concern may also involve
use of caffeine, over-the-counter stimulants, marijuana,
cocaine, alcohol, and other controlled or illicit sub-
stances. Alcohol has been associated with worsened cog-
nitive performance in post-TBI populations and may
interfere with the recovery process [141, 142].
While acute PTH resolve within a few weeks for the ma-
jority of individuals, some may go on to develop persistent
PTH that can cause significant disability. Making matters
more challenging for clinicians, there continues to be a
lack of consensus regarding the management of persistent
PTH, also due to the unmet need of randomized placebo-
controlled trials. Current proper management of persist-
ent PTH requires recognition of the primary headache
type resembling by persistent PTH and tailoring pharma-
cologic and non-pharmacologic treatments to the individ-
ual patient. Based on the different presentations and the
different treatment responses for each headache persistent
PTH are entities apart from PTH.
Despite this, it is judicious to complete a thorough
evaluation and exclude other secondary causes of head-
ache and to provide each patient with an individualized
and multidimensional treatment plan comprising life-
style changes, psychological support, and pharmaco-
logical treatments. Because these headaches can be
disabling and difficult to treat, further evidence-based
approaches to this long-neglected field of research are
needed to improve outcomes for affected patients.
Conclusions
Persistent PTH is a disabling sequela with unknown
pathophysiology and lack of specific treatments. It could
be speculated that persistent PTH results in a
migrainous loop, however, the relationship between per-
sistent PTH and migraine is controversial and highly de-
bated. These disorders share some phenotypic
similarities, furthermore, the history of migraine is a risk
factor for developing persistent PTH and migraine treat-
ment is reported to be efficient in PTH patients.
In contrast, neuroimaging studies found different
structural and functional brain changes, which suggest
that these are distinct entities and have different mecha-
nisms, and in PTH the brain changes could be revers-
ible. Moreover, neurophysiological studies in PTH
patients are sparse and fail to demonstrate specific fea-
tures, while migraine patients present distinct neuro-
physiologic patterns.
Thus, despite some phenotypic similarities persistent
PTH seems a distinct entity and high-quality studies are
further required to investigate the pathophysiologic
mechanisms of this secondary headache, in order to de-
velop new targets for treatment and to prevent disability.
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